Effect of black seed on dextromethorphan o- and n-demethylation in human liver microsomes and healthy human subjects

Drug Metabolism Letters

Volumn 4, Issue 1, 2010, Pages 51-55

  Al Jenoobi, F I ^a   Al Thukair, A A ^a   Abbas, F A ^a   Ansari, M J ^a   Alkharfy, K M ^a   Al Mohizea, A M ^a   Al Suwayeh, S A ^a   Jamil, S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Black seed; CYP2D6; CYP3A4; Dextromethorphan; Human volunteers; Interaction; Metabolism; Microsomes

Indexed keywords

3 METHOXYMORPHINAN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; NIGELLA SATIVA EXTRACT; UNCLASSIFIED DRUG; 3-METHOXYMORPHINAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; DRUG DERIVATIVE; PLANT EXTRACT;

ADULT; ARTICLE; BLACK CUMIN; DEMETHYLATION; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; LIVER MICROSOME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PLANT SEED; URINE;

ADOLESCENT; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DEXTROMETHORPHAN; DEXTRORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICROSOMES, LIVER; NIGELLA SATIVA; PLANT EXTRACTS; SEEDS; YOUNG ADULT;

EID: 77953278946     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231210790980435     Document Type: Article

References (39)

1. Shapiro, L.E.; Shear, N.H. Drug-drug interactions: how scaredshould we be?. Can. Med. Assoc. J., 1999, 161(10), 1266-1267.
2. Jankel, C.A.; Fitterman, L.K. Epidemiology of drug-drug interac-tions as a cause of hospital admissions. Drug Saf., 1993, 9(1), 51-59.
3. Eisenberg, D.M.; Kessler, R.C.; Foster, C.; Norlock, F.E.; Calkins,D.R.; Delbanco, T.L. Unconventional medicine in the UnitedStates: prevalence, cost and patterns of use. N. Engl. J. Med., 1993,328(4), 246-252.
4. Maclennan, A.H.; Wilson, D.H.; Taylor, A.W. Prevalence and costof alternative medicine in Australia. Lancet, 1996, 347(9001), 569-573.
5. Fisher, P.; Ward, A. Complementary medicine in Europe. Br. Med.J., 1994, 309(6947), 107-111.
6. Al-Rowais, N.A. Herbal medicine in the treatment of diabetesmellitus. Saudi Med. J., 2002, 23(11), 1327-1331.
7. Huang, S.M.; Lesko, L.J. Drug-drug, drug-dietary supplement, anddrug-citrus fruit and other food interactions: What have we learned?. J. Clin. Pharmacol., 2004, 44(6), 559-569.
8. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gen-try, W.B.; Ang, Y.W. Cytochrome P450 phenotypic ratios for pre-dicting herb-drug interactions in humans. Clin. Pharmacol.Therap., 2002, 72(3), 276-287.
9. Diamond, B.J.; Shifflett, S.C.; Feiwel, N. Ginkgo biloba extract:mechanisms and clinical indications. Arch. Phys. Med. Rehabil.,2000, 81(5), 668-678.
10. Galluzzi, S.; Zanetti, O.; Binetti, G. Coma in a patient with Alz-heimer's disease taking low dose trazodone and ginkgo biloba. J.Neurol. Neurosurg. Psychiatry., 2000, 68(5), 679-683.
11. Guyonnet, D.; Belloir, C.; Suscetet, M.; Siess, M.H.; Le Bon, A.M.Liver subcellular fractions from rats treated by organosulfar com-pounds from Allium modulate mutagen activation. Mutat. Res.,2000, 466(1), 17-26.
12. Zhou, S.; Chan, E.; Pan, S.Q.; Huang, M; Lee, E.J. Pharmacoki-netic interactions of drugs with St John s Wort. J. Psychpharma-col., 2004, 18(2), 262-276.
13. Ali, B.H.; Blunden, G. Pharmacological and toxicological proper-ties of Nigella Sativa. Phytother. Res., 2003, 17(4), 299-305.
14. El-Tahir, K.; Ashour, M.M.; Al-Harbi, M.M. The respiratory ef-fects of the volatile oil of the black seed (Nigella Sativa) in guinea-pigs: elucidation of the mechanism(s) of action. Gen. Pharmacol.,1993, 24(5), 1115-1122.
15. Daba, M.H.; Abdel-Rahman, M.S. Hepatoprotective activity ofthymoquinone in isolated rat hepatocytes.Toxicol. Lett., 1998,95(1), 23-29.
16. Nagi, M.N.; Alam, K.; Badary, O.A.; al-Shabanah, O.A.; al-Sawaf, H.A., al- Bekairi A.M. Thymoquinone protects against carbon tet-rachloride hepatotoxicity in mice via an antioxidant mechanism. Biochem. Mol. Biol. Int., 1999, 47(1), 153-159.
17. Worthen, D.R.; Ghosheh, O.A.; Crooks, P.A. The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. Anticancer Res., 1998, 18(3A), 1527-1532.
18. Ibrahim, Z.S., Ishizuka, M., Soliman, M., ElBohi, K.; Sobhy, W., Muzandu, K., Elkattawy, A.M., Sakamoto, K.Q., Fujita, S. Protection by Nigella Sativa against carbon tetrachloride-induced down-regulation of hepatic cytochrome P450 isozymes in rats. Jpn. J.Vet. Res., 2008, 56(3), 119-28
19. Schadel, M.; Otton, S.V.; Kalow, W.; Sellers, E.M. The pharma-cokinetics of dextromethorphan and metabolites in humans: influence of CYP2D6 phenotype and quinidine inhibition. J. Clin. Psy-chopharmacol., 1995, 15(4), 263-269.
20. Barnhart, J.W. The urinary excretion of dextromethorphan andthree metabolites in dogs and humans. Toxicol. Appl. Pharmacol.,1980, 55(1), 43-48.
21. Gorski, J.C.; Jones, D.R.; Wrighton, S.A.; Hall, S.D. Characteriza-tion of dextromethorphan N-demethylation by human liver micro-somes. Biochem. Pharmacol., 1994, 48(1) 173-182.
22. Kerry, N.L.; Somogyi, A.A.; Bochner, F.; Mikus, G. The role ofCYP2D6 in primary and secondary oxidative metabolism of dex-tromethorphan: in vitro studies using human liver microsomes. Br.J. Clin. Pharmacol., 1994, 38(3), 243-248.
23. Hu, O.Y.; Tang, H.S.; Lane, H.Y.; Chang, W.H.; Hu, T.M. Novelsingle-point plasma or saliva dextromethorphan method for deter-mining CYP2D6 activity. J. Pharmacol. Exp. Ther., 1998, 285(3),955-960.
24. Takashima, T.; Murase, S.; Iwasaki, K., Shimada, K. Evaluation ofdextromethorphan metabolism using hepatocytes from CYP2D6poor and extensive metabolizers. Drug. Metab. Pharmacokinet.,2005, 20(3), 177-182.
25. Wojtczak, A.; Rychlik-Sych, M.; Krochmalska-Ulacha, E., Skretkowicz, J. CYP2D6 phenotyping with dextromethorphan. Pharmacol. Rep., 2007, 59(6), 734-738.
26. [26] Spanakis, M.; Vizirianakis, I.S.; Mironidou-Tzouveleki, M., Niopas, I.A. validated SIM GC/MS method for the simultaneousdetermination of dextromethorphan and its metabolites dextror-phan, 3-methoxymorphinan and 3- hydroxymorphinan in biologicalmatrices and its application to in vitro CYP2D6 and CYP3A4 inhi-bition study. Biomed Chromatogr., 2009, May 14. [Epub ahead ofprint].
27. Yu, A.; Haining, R.L. Comparative contribution to dextromethor-phan metabolism by cytochrome P450 isoforms in vitro: can dex-tromethorphan be used as a dual probe for both CYP2D6 andCYP3A activities?. Drug Metab Dispos., 2001, 29(11), 1514-1120.
28. Ducharme, J.; Abddullah, S.; Wainer, I.W. Dextromethorphan asan in vivo probe for the simultaneous determination of CYP2D6and CYP3A activity. J. Chromatogr. B: Biomed. Appl., 1996,678(1), 113-128.
29. Funck- Brentano, C.; Boelle, P.Y.; Verstuyft, C.; Bornert, C.; Bec-quemont, L.; Poirier, J.M. Measurement of CYP2D6 and CYP3A4activity in vivo with dextromethorphan: sources of variability andpredictors of adverse effects in 419 healthy subjects. Eur. J. Clin.Pharmacol., 2005, 61(11), 821-829.
30. Jones, D.R.; Gorski, J.C.; Hamman, M.A.; Hall, S.D. Quantifica-tion of dextromethorphan and metabolites: a dual phenotypicmarker for cytochrome P450 3A4/5 and 2D6 activity. J. Chroma-togr. B. Biomed. Appl., 1996, 678(1), 105-111.
31. Bendriss, E.K.; Markoglou, N.; Wainer, I.W. High-performanceliquid chromatography assay for simultaneous determination ofdextromethorphan and its main metabolites in urine and in micro-somal preparations. J. Chromatogr. B. Biomed Sci. Appl., 2001,754(1), 209-215.
32. Min, D.I.; Ku, Y.M.; Vichiendilokkul, A.; Fleckenstein, L.L. Aurine. metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and predictionof cyclosporine clearance in healthy volunteers. Pharmacotherapy,1999, 19(6), 753-759.
33. Kashuba, A.D.; Nafziger, A.N.; Kearns, G.L.; Leeder, J.S., Gotschall, R., Gaedigk, A., Bertino, J.S. Jr. Limitations of dex-tromethorphan N-demethylation as a measure of CYP3A activity.Pharmacogenetics, 1999, 9(4), 453-462.
34. Kuo, B.P.; Hu, O.Y.; Hsiong, C.H.; Pao, L.H.; Chen, T.S.; Hung, C.F. Single- point plasma or urine dextromethorphan method fordetermining CYP3A activity. Biopharm. Drug Dispos., 2003,24(9), 367-373.
35. [35] Bachmann, K.A.; Ghosh, R. The use of in vitro methods to predictin vivo pharmacokinetics and drug interactions. Curr. Drug Metab.,2001, 2(3), 299-314.
36. Houston, J.B.; Carlile, D.J. Prediction of hepatic clearance frommicrosomes, hepatocytes, and liver slices. Drug Metab. Rev., 1997,29(4), 891-922.
37. Guillouzo, A.; Rialland, L.; Fautrel, A.; Guyomard, C. Survival andfunction of isolated hepatocytes after cryopreservation. Chem. Biol.Interact., 1999, 121, 7-16.
38. Renwick, A.B.; Watts, P.S.; Edwards, R.J.; Barton, P.T.; Guyonnet, I., Price, R.J., Tredger, J., Pelkonen, O., Boobis, A.R., Lake, B.G. Differential maintenance of cytochrome P450 enzymes in culturedprecision-cut human liver slices. Drug Metab. Dispos., 2000, 28,1202-1209.
39. Pelkonen, O. Human CYPs: in vivo and clinical aspects. DrugMetab. Rev., 2002, 34, 37-46.